Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961492 | 0.91 | HSD11B1 (0.47) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL966396 | 0.91 | HSD11B1 (0.47) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL16669434 | 0.76 | HSD11B1 (0.40) | HSD11B1KMT2AKDM4EHRH3 | |
| SCHEMBL12946633 | 0.76 | HSD11B1 (0.40) | HSD11B1KMT2AKDM4EHRH3 | |
| SCHEMBL12915091 | 0.75 | HSD11B1 (0.49) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL12915107 | 0.75 | HSD11B1 (0.49) | HSD11B1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL963349 | 0.74 | HPGD (0.39) | HSD11B1KMT2AMEN1LMNADPP4 | |
| SCHEMBL960871 | 0.74 | HPGD (0.39) | HSD11B1KMT2AMEN1LMNADPP4 | |
| Trifluoroacetic Acid SCHEMBL965196 | 0.74 | SLC1A2 (0.35) | — | |
| SCHEMBL961417 | 0.73 | HPGD (0.42) | HSD11B1KMT2AMEN1LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| EP-2454270-B1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2015-02-11 | — | — | EP | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | HSD11B1 115/4885CNR1 1050/4885KMT2A 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.